| scholarly article | Q13442814 |
| P50 | author | Antoine Néel | Q61651271 |
| Anaïs Wahbi | Q88333297 | ||
| Cécile Goujard | Q88521925 | ||
| P2093 | author name string | Cédric Bretonnière | |
| Dorothée Carpentier | |||
| Guillaume Geri | |||
| Olivier Decaux | |||
| Hervé Maisonneuve | |||
| Mohamed Hamidou | |||
| Jacques Pouchot | |||
| Laurence Fardet | |||
| Pascal Godmer | |||
| Benoit Tessoulin | |||
| Arnaud Mari | |||
| Julien Boileau | |||
| Jean-Marc Ziza | |||
| P2860 | cites work | Lymph node IL-18 expression in adult-onset Still's disease. | Q51824485 |
| The Logistic Organ Dysfunction system. A new way to assess organ dysfunction in the intensive care unit. ICU Scoring Group. | Q52199824 | ||
| Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. | Q54105583 | ||
| Interleukin-18 as a novel diagnostic marker and indicator of disease severity in adult-onset Still's disease | Q74242469 | ||
| Proposal for a new set of classification criteria for adult-onset still disease | Q78069999 | ||
| Clinical manifestations but not cytokine profiles differentiate adult-onset Still's disease and sepsis | Q84973391 | ||
| Adult-onset Still's disease | Q26852631 | ||
| Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome | Q28239135 | ||
| APACHE II: a severity of disease classification system | Q29547729 | ||
| A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study | Q29615430 | ||
| Reactive haemophagocytic syndrome in adult-onset Still's disease: a report of six patients and a review of the literature | Q33370577 | ||
| Life-threatening complications of adult-onset Still's disease | Q33412732 | ||
| Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients | Q33414045 | ||
| Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features, predictive factors, and prognosis in 21 patients | Q33420069 | ||
| Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in west France | Q33578168 | ||
| Preliminary criteria for classification of adult Still's disease | Q34405573 | ||
| Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis | Q35553556 | ||
| Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases | Q35555229 | ||
| Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study | Q35557906 | ||
| Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome | Q35847631 | ||
| Myocarditis in adult-onset still disease | Q36150742 | ||
| Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review. | Q36195807 | ||
| Understanding organ dysfunction in hemophagocytic lymphohistiocytosis | Q37144156 | ||
| Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial | Q37735696 | ||
| Biological treatment in adult-onset Still's disease | Q38049762 | ||
| Application of the 2016 EULAR/ACR/PRINTO Classification Criteria for Macrophage Activation Syndrome in Patients with Adult-onset Still Disease. | Q40060914 | ||
| Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. | Q40218234 | ||
| Tocilizumab in refractory adult Still's disease | Q40350291 | ||
| Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients | Q40368756 | ||
| Adult-onset Still disease with hemophagocytic syndrome treated with cyclosporine | Q40492169 | ||
| Rapid responses to anakinra in patients with refractory adult-onset Still's disease | Q40507008 | ||
| Etanercept in the treatment of adult patients with Still's disease | Q40578875 | ||
| May anakinra be used earlier in adult onset Still disease? | Q43080826 | ||
| Infliximab in the treatment of adult Still's disease refractory to conventional therapy | Q43640728 | ||
| Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group | Q44267568 | ||
| Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease | Q44554787 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P304 | page(s) | 88 | |
| P577 | publication date | 2018-04-11 | |
| P1433 | published in | Critical Care | Q5186602 |
| P1476 | title | Diagnostic and management of life-threatening Adult-Onset Still Disease: a French nationwide multicenter study and systematic literature review | |
| P478 | volume | 22 |
| Q90177179 | Adult-onset Still's disease revealed by a complete atrioventricular block, totally regressive under corticosteroid therapy |
| Q90464748 | Anakinra in Still's disease: a profile of its use |
| Q91910547 | Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts |
| Q64235820 | Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study |
| Q57143910 | Mechanisms, biomarkers and targets for adult-onset Still's disease |
| Q101237305 | Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients |
Search more.